"Liraglutide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
| Descriptor ID |
D000069450
|
| MeSH Number(s) |
D06.472.317.469.500.500.500
|
| Concept/Terms |
NN 2211- NN 2211
- 2211, NN
- NN2211
- NN-2211
|
Below are MeSH descriptors whose meaning is more general than "Liraglutide".
Below are MeSH descriptors whose meaning is more specific than "Liraglutide".
This graph shows the total number of publications written about "Liraglutide" by people in this website by year, and whether "Liraglutide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 9 | 1 | 10 |
| 2018 | 12 | 9 | 21 |
| 2019 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Liraglutide" by people in Profiles.
-
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. Cell Rep. 2019 08 06; 28(6):1447-1454.e4.
-
IDegLira: combining efficacy, durability, and convenience? Lancet Diabetes Endocrinol. 2019 08; 7(8):584-585.
-
Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice. Biochem Biophys Res Commun. 2019 06 25; 514(2):386-392.
-
Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2019 Sep; 56(9):1051-1060.
-
Microvascular and macrovascular effects of liraglutide. Int J Cardiol. 2019 07 01; 286:17-18.
-
Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology. 2019 06; 69(6):2414-2426.
-
Gender-related issues in the pharmacology of new anti-obesity drugs. Obes Rev. 2019 03; 20(3):375-384.
-
Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 03; 1864(3):326-334.
-
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation. 2018 12 18; 138(25):2884-2894.
-
GLP-1 receptor agonists and cardiovascular outcome trials: An update. Hellenic J Cardiol. 2019 Nov - Dec; 60(6):347-351.